Conclusions: Semaglutide as an adjunctive therapy demonstrates significant and sustained improvements in IIH-related outcomes, including visual disturbances, papilledema, and headache symptoms
Your provider may recommend: Shorter time at the 2.5 mg initiation dose (3 weeks instead of 4) More aggressive titration to reach therapeutic levels sooner Targeting higher maintenance doses (12.5 to 15 mg) from the outset Closer monitoring of side effects to balance speed with tolerance The microdosing alternative for sensitive switchers Not everyone needs or wants to follow the standard titration
Adjusted True Value Scores based on updated scoring data
Beyond weight loss, semaglutide GLP-1 also offers metabolic health benefits, improving blood pressure, cholesterol levels, and blood sugar control
Take phone calls standing up
Yeah, the mechanism of the Wegovy and the tirzepatide, these injectables, they mimic a hormone that our bodies make called GLP-1, and then tirzepatide, also GIP, to gut hormones, such as appetite